Bernstein lowered the firm’s price target on Abbott (ABT) to $125 from $154 and keeps an Outperform rating on the shares. The firm notes the company’s Q4 sales of $11.46B grew 3.0% organic and missed consensus by 3%. Nutrition declined 9% to $1.94B and missed by 12% or about $255M, which made up 75% of the $345M sales miss in the quarter.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target lowered to $140 from $155 at Citi
- Abbott price target lowered to $122 from $146 at Wells Fargo
- Buy Rating on Abbott: Near‑Term Nutrition Headwinds Offset by High-Growth MedTech and Attractive 2026 Valuation
- Abbott Laboratories Earnings Call: Devices Offset Nutrition Drag
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!